Turnstone Biologics (NASDAQ:TSBX) Posts Quarterly Earnings Results

Turnstone Biologics (NASDAQ:TSBX) issued its earnings results on Tuesday. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.13, Zacks reports.

Turnstone Biologics Trading Down 1.2 %

Shares of Turnstone Biologics stock opened at $0.53 on Friday. The stock has a 50 day moving average price of $0.54 and a 200-day moving average price of $1.69. Turnstone Biologics has a one year low of $0.44 and a one year high of $5.75.

Analyst Ratings Changes

A number of research firms have issued reports on TSBX. Bank of America downgraded Turnstone Biologics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $10.00 to $0.50 in a research note on Monday, October 14th. Piper Sandler lowered their price objective on shares of Turnstone Biologics from $20.00 to $3.75 and set an “overweight” rating for the company in a research report on Monday, August 19th.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.